Organisation paid for research Program year 2025 Source: CMS Open Payments

Premier Clinical Research Dba Stat Research

Neither a doctor nor a teaching hospital

Research payments

$951,864

58 payments

Through program year 2025, Premier Clinical Research Dba Stat Research is reported as receiving $951,864 in research payments, across 58 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $138,661 11
2024 Research $413,318 13
2023 Research $13,934 4
2022 Research $30,912 3
2021 Research $68,167 17
2020 Research $271,226 7
2019 Research $15,647 3

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $318,039 9 payments
  2. Sumitomo Pharma America, Inc. $273,254 19 payments
  3. Becton, Dickinson and Company $254,050 3 payments
  4. Allergan Inc. $58,576 19 payments
  5. Sagent Pharmaceuticals, Inc. $35,682 3 payments
  6. Amgen Inc. $12,263 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multi-Center, Prospective, Observational Study of Patients Being Treated With Orgovyx $259,370 16 payments
  2. Veritor Antigen Assay $254,050 3 payments
  3. A Randomized, Double-Blind, Placebo Controlled, 2-Arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (Neptunus-1) $148,890 3 payments
  4. A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome $125,701 2 payments
  5. CAMELOT Trial (Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID19) $35,682 3 payments
  6. A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $26,470 6 payments
  7. An International Prospective Open-label, Multi-center, Randomized Phase III Study comparing [177Lu] Lu-PSMA-617 versus Observation to delay castration or disease recurrence in adult male patients with PSMA positive Oligometastatic Prostate Cancer (OMPC) $21,300 1 payment
  8. A Multi-Center, Prospective, Observational Study of Patients Being Treated With Orgovyx $13,884 3 payments
  9. 46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) $13,516 4 payments
  10. A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis $13,516 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record